The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.
User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
A user is concerned about low hair density 12 months after a hair transplant and is not using finasteride or minoxidil, only taking biotin. They are seeking advice on whether this is normal, if starting medication now would help, and when to consider a second procedure.
A 34-year-old male shares his 4-month progress using Minoxidil 5%, Finasteride 0.2% liquid, Tretinoin 0.01% liquid, and a dermaroller once a week for hair regrowth, reporting no side effects and noticing baby hairs on the crown. He prefers topical treatments over oral Finasteride and is optimistic about further progress.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.